Why You Should Watch PDL BioPharma, Inc. (PDLI)?

PDL BioPharma, Inc. (NASDAQ:PDLI) is one of the active stocks and its unusual movement is raising eyebrows among traders. Now trading with a market value of 277.98M, the company has a mix of catalysts and obstacles that spring from the nature of its operations. As the day-to-day narrative ebbs and flows for this company, it is more important than ever to step back and get a bird’s eye view of the fundamental reality under the surface of this story.

PDL BioPharma, Inc. (NASDAQ:PDLI) Fundamentals That Matter

It’s generally a good idea to start with the most fundamental piece of the picture: the balance sheet. The balance sheet health of any company plays a key role in its ability to meet its obligations and maintain the faith of its investment base. For PDLI, the company currently has 284.94 million of cash on the books, which is offset by 0 in current liabilities. The trend over time is important to note. In this case, the company’s debt has been falling. The company also has 0 in total assets, balanced by 759.08 million in total liabilities, which should give you a sense of the viability of the company under any number of imagined business contexts.

PDL BioPharma, Inc. saw 8338 in free cash flow last quarter, representing a quarterly net change in cash of 109649. Perhaps most importantly where cash movements are concerned, the company saw about 8175 in net operating cash flow.

PDL BioPharma, Inc. (NASDAQ:PDLI) Revenue Growth Potential

As far as key trends that demonstrate something of the future investment potential of this stock, we need to take a closer look at the top line, first and foremost. Last quarter, the company saw 22.53 million in total revenues. That represents a quarterly year/year change in revenues of 3.07% in sequential terms, the PDLI saw sales grow by 2.73%.

But what about the bottom line? After all, that’s what really matters in the end. PDL BioPharma, Inc. is intriguing when broken down to its core data. The cost of selling goods last quarter was 12.35 million, yielding a gross basic income of 34.87 million. For shareholders, given the total diluted outstanding shares of 117.29M, this means overall earnings per share of -40.

Is PDL BioPharma, Inc. (NASDAQ:PDLI) Valuation Attractive

Looking ahead at valuations, according to the consensus, the next fiscal year is forecast to bring about 0.06 in total earnings per share. However, one should always remember: the trends are more important than the forecasts. This continues to be an interesting story, and we look forward to updating it again soon on PDL BioPharma, Inc..